Skip to main content
. 2016 Jan 22;9:461–468. doi: 10.2147/OTT.S96199

Figure 2.

Figure 2

PFS for EGFR-TKI treatment.

Notes: The PFS curves of EGFR-TKI-treated patients with different HDL-C kinetics. Patients whose HDL-C >0.945 mmol/L and never decreased during treatment of EGFR-TKI have an increasing trend on the subsequent time points.

Abbreviations: PFS, progression-free survival; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; HDL-C, high-density lipoprotein cholesterol.